Observational studyBMC nephrology2025
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ventilator-Associated Pneumonia: The Role of Kidney-Lung Crosstalk and Renal Replacement Therapy, a Narrative Review.Journal of clinical medicine · 2026Review
- Impact of COVID-19 on Renal Function: Analysis of Acute Kidney Injury Across Three Pandemic Waves.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study evaluated the diagnostic and prognostic value of biomarkers, including soluble forms of the receptor for advanced glycation end-products (s-RAGE), soluble urokinase plasminogen activator receptor (SuPAR), and others, for the occurrence of early-onset acute kidney injury (EO-AKI), EO-AKI non-recovery, day-90 major adverse kidney events (MAKE-90), and day-90 mortality in critically ill patients with Coronavirus Disease-19 (Covid-19).
methodsA single-center, prospective study was conducted at the University Hospital of Clermont-Ferrand, France, between March 2020 and February 2021. The study included adult patients suffering from severe pneumonia caused by the SARS-CoV-2 virus, who were admitted to the hospital's intensive care unit. The urinary biomarkers that constituted the focus of the study included SuPAR, liver fatty-acid-binding proteins (L-FABP), urinary tissue inhibitor of metalloprotease-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) ([TIMP-2]*[IGFBP7]). The serum biomarkers that were studied included s-RAGE and inflammatory markers such as interleukin (IL)-1β, IL-6 and tumor necrosis factor (TNF)-α. Assessed outcomes included EO-AKI, EO-AKI non-recovery, MAKE-90, and day-90 mortality. A range of statistical methodologies were employed for the analysis.
resultsThe study comprised a total of 149 patients. The prevalence of EO-AKI was found to be 30.9%. In 56.5% of cases, EO-AKI non-recovery occurred. MAKE-90 was 43.6% and day-90 mortality was 37%. Procalcitonin was found to be associated with EO-AKI, whilst TNF-α was associated with EO-AKI non-recovery. Furthermore, elevated levels of s-RAGE and SuPAR levels were found to be associated with MAKE-90.
conclusionsIn critically ill patients with confirmed diagnosis of COVID-19, the presence of biomarkers had limited predictive value for the occurrence of EO-AKI. However, TNF-α was found to be associated with EO-AKI non-recovery and s-RAGE and SuPAR were associated with an increased risk of day-90 mortality. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.